- Home
- CVKD vs BOLD Comparison
CVKD vs BOLD Comparison
Compare CVKD & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- BOLD
- Stock Information
- Founded
- CVKD 2022
- BOLD 2018
- Country
- CVKD United States
- BOLD United States
- Employees
- CVKD N/A
- BOLD N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- BOLD
- Sector
- CVKD Health Care
- BOLD
- Exchange
- CVKD Nasdaq
- BOLD Nasdaq
- Market Cap
- CVKD 33.7M
- BOLD 30.3M
- IPO Year
- CVKD 2023
- BOLD 2024
- Fundamental
- Price
- CVKD $15.50
- BOLD $1.50
- Analyst Decision
- CVKD Strong Buy
- BOLD Hold
- Analyst Count
- CVKD 1
- BOLD 1
- Target Price
- CVKD $32.00
- BOLD N/A
- AVG Volume (30 Days)
- CVKD 21.0K
- BOLD 63.1K
- Earning Date
- CVKD 05-08-2025
- BOLD 05-16-2025
- Dividend Yield
- CVKD N/A
- BOLD N/A
- EPS Growth
- CVKD N/A
- BOLD N/A
- EPS
- CVKD N/A
- BOLD N/A
- Revenue
- CVKD N/A
- BOLD N/A
- Revenue This Year
- CVKD N/A
- BOLD N/A
- Revenue Next Year
- CVKD N/A
- BOLD N/A
- P/E Ratio
- CVKD N/A
- BOLD N/A
- Revenue Growth
- CVKD N/A
- BOLD N/A
- 52 Week Low
- CVKD $5.70
- BOLD $1.06
- 52 Week High
- CVKD $22.90
- BOLD $12.26
- Technical
- Relative Strength Index (RSI)
- CVKD 41.03
- BOLD N/A
- Support Level
- CVKD $15.29
- BOLD N/A
- Resistance Level
- CVKD $17.00
- BOLD N/A
- Average True Range (ATR)
- CVKD 0.80
- BOLD 0.00
- MACD
- CVKD -0.02
- BOLD 0.00
- Stochastic Oscillator
- CVKD 9.50
- BOLD 0.00
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.